Nick is a renowned NGS leader with international executive management experience in healthcare and technology businesses.
He was founding CEO of Solexa, from the time of its spin-out from the University of Cambridge in 2000 to its NASDAQ listing in 2005. He led the development of the world’s leading Next Generation DNA Sequencing (NGS) technology, which became the basis of Illumina’s NGS product line.
Currently pursuing a portfolio career, with a focus on disruptive genomics technologies, he is a Non-Executive Director of Evonetix Ltd and Bioventix plc. Prior board and leadership positions in the UK, Belgium, USA and Japan include DNA Electronics, inventor of semiconductor sequencing, BioGazelle, Oxford Cancer Biomarkers, Pronota, Solexa, Rapigene, Innovex, Quintiles and Celltech, as well as a Trustee of the Association of Medical Research Charities.
Nick has an MBA from London Business School and is a graduate in engineering.